| Name | Title | Contact Details |
|---|---|---|
Tom Gordon |
Vice President of Sales, Western U.S. and Canada | Profile |
Bringing over 75 years of combined industry experience, Incline P&C Group is the premier insurance program market services firm. Privately owned and operated with an exclusive focus on the program insurance market, the executive teams experience and expertise combined with effective underwriting discipline and risk management provides each client with various platforms and associated services to meet almost any need in the industry.
Two Rivers is a 12 attorney law firm concentrating in the area of workers compensation litigation, primarily for employers and insurance companies, appellate practice and subrogation claims. We have offices strategicaly located Richmond, Virginia, the state capital and in Christiansburg in the New River Valley of Western Virginia. From these two locations, we practice across the Commonwealth. Two Rivers also practices in the District of Columbia and West Virginia.
FM Global is a Rhode Island-based insurance company that specializes in property insurance, risk consulting and loss prevention for businesses.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.